Contribution of @entity229 to the effectiveness of @entity11558 in multiple XXXX .

@entity1 @entity137 @entity229 @entity1582 @entity1503 @entity11558
The Eastern Cooperative Oncology Group evaluated @entity11558 in 89 @entity1 with advanced refractory or relapsing multiple @entity1582 . @entity11558 was initially used as a single agent administered orally at 200 mg/m2/day for the first 3 weeks of each 4-week cycle. When this regimen proved to be ineffective, it was modified first by increasing the dose of @entity11558 to 280 mg/m2/day and subsequently by adding @entity229 at 75 mg for the first 7 days of each 28-day cycle. None of the 39 @entity1 receiving @entity11558 without @entity229 had an objective response, while two @entity1 had minimal objective improvement (25%-50% decrease in M protein with symptomatic improvement). Only 14% of these @entity1 had objective or symptomatic response or both. In contrast, @entity1 treated with @entity11558 plus @entity229 had a 22% objective response rate, with another 14% showing lesser degrees of objective improvement. Fifty-one percent of the @entity1 treated with this regimen had either objective or symptomatic improvement or both. Severe (grade 3) @entity137 was seen in nearly two-thirds of the @entity1 on the higher-dose @entity11558 regimens compared with 37% of the @entity1 receiving low-dose @entity11558 ; however, in most instances this represented rapidly reversible @entity1503 . Because all but one of the @entity1 responding to @entity11558 plus @entity229 had experienced previous treatment failure on regimens containing @entity229 in similar dose and schedules, it is unlikely that the responses are due to @entity229 alone. Instead, this study suggests that the activity of @entity11558 in multiple @entity1582 is dependent on the concomitant administration of @entity229 and that the combination regimen appears to be synergistic.
